Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRNA 
Moderna Inc (MRNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: MRNA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
27 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $46.96
Year Target Price $46.96
| 5 | Strong Buy |
| 1 | Buy |
| 17 | Hold |
| 0 | Under performing |
| 4 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.77% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.50B USD | Price to earnings Ratio - | 1Y Target Price 47.59 |
Price to earnings Ratio - | 1Y Target Price 47.59 | ||
Volume (30-day avg) - | Beta 1.86 | 52 Weeks Range 23.15 - 129.39 | Updated Date 06/29/2025 |
52 Weeks Range 23.15 - 129.39 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -105.67% | Operating Margin (TTM) -972.22% |
Management Effectiveness
Return on Assets (TTM) -15.84% | Return on Equity (TTM) -29.34% |
Valuation
Trailing PE - | Forward PE 32.47 | Enterprise Value 5273907831 | Price to Sales(TTM) 3.31 |
Enterprise Value 5273907831 | Price to Sales(TTM) 3.31 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA 4.64 | Shares Outstanding 386742016 | Shares Floating 360977080 |
Shares Outstanding 386742016 | Shares Floating 360977080 | ||
Percent Insiders 7.28 | Percent Institutions 73.73 |
Analyst Ratings
Rating 3.22 | Target Price 46.96 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 17 | Sell 3 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Moderna Inc
Company Overview
History and Background
Moderna was founded in 2010, pioneering messenger RNA (mRNA) therapeutics and vaccines. Initially focused on drug discovery, the company gained prominence with its rapid development of a COVID-19 vaccine.
Core Business Areas
- mRNA Therapeutics and Vaccines: Develops and commercializes mRNA-based vaccines and therapies for infectious diseases, cancer, and other conditions.
Leadership and Structure
The CEO is Stu00e9phane Bancel. Moderna operates with a functional organizational structure, prioritizing research and development.
Top Products and Market Share
Key Offerings
- Spikevax (COVID-19 Vaccine): Moderna's primary revenue driver. Market share has fluctuated with global vaccine demand and competition. Competitors: Pfizer/BioNTech (BNTX), Johnson & Johnson (JNJ), Novavax (NVAX).
- Future mRNA Products: Pipeline products targeting various infectious diseases, cancer, and rare diseases. Market share is currently negligible but represents future growth potential. Competitors: Pfizer/BioNTech (BNTX), CureVac (CVAC), various pharmaceutical companies.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are highly competitive and regulated. The mRNA therapeutics market is rapidly growing, driven by the success of COVID-19 vaccines.
Positioning
Moderna is a leading mRNA vaccine and therapeutics company with a first-mover advantage in the field. Its competitive advantages include its proprietary mRNA technology platform and rapid vaccine development capabilities.
Total Addressable Market (TAM)
The global vaccines market is projected to reach hundreds of billions of dollars. Moderna is well-positioned to capture a significant portion of this TAM with its mRNA technology.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology
- Rapid vaccine development
- Strong research and development capabilities
- Established manufacturing infrastructure
- Significant cash reserves
Weaknesses
- Reliance on COVID-19 vaccine revenue
- Limited track record of commercializing non-vaccine products
- Patent disputes with competitors
- High operating expenses
Opportunities
- Expansion into new therapeutic areas (cancer, rare diseases)
- Development of combination vaccines
- Partnerships with pharmaceutical companies
- Geographic expansion
- Leveraging mRNA technology for personalized medicine
Threats
- Competition from established pharmaceutical companies
- Patent challenges and intellectual property disputes
- Regulatory hurdles
- Declining COVID-19 vaccine demand
- Adverse events associated with mRNA vaccines
Competitors and Market Share
Key Competitors
- PFE
- BNTX
- MRNA
Competitive Landscape
Moderna has a leading position in mRNA vaccine technology, but faces competition from established pharmaceutical companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Growth was substantial during the pandemic due to COVID-19 vaccine sales.
Future Projections: Future growth is projected to be driven by new mRNA products and expanded vaccine offerings, but revenue will likely fluctuate
Recent Initiatives: Moderna is investing heavily in research and development to expand its mRNA platform and pipeline. They're also pursuing partnerships with other pharmaceutical companies.
Summary
Moderna is a leader in mRNA technology, benefiting from the success of its COVID-19 vaccine, but its future hinges on diversifying its product pipeline beyond COVID-19. Strong research capabilities and cash reserves position the company well. Declining COVID-19 vaccine demand and competition pose challenges. Successful development of new mRNA products is crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Moderna's Investor Relations website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moderna Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-12-07 | CEO & Director Mr. Stéphane Bancel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5800 | Website https://www.modernatx.com |
Full time employees 5800 | Website https://www.modernatx.com | ||
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.